Please login to the form below

Not currently logged in
Email:
Password:

Boehringer/ Elan antibody deal

Boehringer Ingelheim has announced a partnership with Elan to develop and manufacture antibody-based therapeutics

Boehringer Ingelheim has announced a partnership with Ireland-based Elan to develop and manufacture antibody-based therapeutics.

German drugmaker, Boehringer said the global deal will see Elan lead the discovery and clinical development of antibodies, with Boehringer to take over the clinical manufacturing and regulatory filing.

"The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim's process development and production capabilities," said Dr Johannes Roebers, head of biologic strategy, planning and operations at Elan.

Elan is a biotech with a focus on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Financial details were not disclosed.

The partnership will make use of Boehringer's High Expression Technology (BI HEX) platform, which aims to speed up development times for biological entities, such as antibodies.

"This is a first step in our new strategy engaging our technology platforms at a very early stage in product development," said Simon Sturge, corporate senior vice president of Boehringer's biopharmaceutical division.

Dr Dale Schenk, chief scientific officer, Elan, said the partnership would increase the productivity and potential of the company's development plans for antibodies: "These programmes are broad in scope and are innovative across technology, targets and possible disease application."

10th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics